Ahmed, M. M., Johnson, N. R., Boyd, T. D., Coughlan, C., Chial, H. J., & Potter, H. (2021). Innate immune system activation and neuroinflammation in down syndrome and neurodegeneration: Therapeutic targets or partners? Frontiers in Aging Neuroscience, 13, 718426. https://doi.org/10.3389/fnagi.2021.718426

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alboni, S., Cervia, D., Sugama, S., & Conti, B. (2010). Interleukin 18 in the CNS. Journal of Neuroinflammation, 7, Article 9. https://doi.org/10.1186/1742-2094-7-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alboni, S., Tascedda, F., Uezato, A., Sugama, S., Chen, Z., Marcondes, M. C. G., et al. (2025). Interleukin 18 and the brain: Neuronal functions, neuronal survival and psycho-neuro-immunology during stress. Molecular Psychiatry, 30(7), 3197–3208. https://doi.org/10.1038/s41380-025-02951-z

Article  PubMed  PubMed Central  Google Scholar 

Boraschi, D., Lucchesi, D., Hainzl, S., Leitner, M., Maier, E., Mangelberger, D., et al. (2011). IL-37: A new anti-inflammatory cytokine of the IL-1 family. European Cytokine Network, 22(3), 127–147. https://doi.org/10.1684/ecn.2011.0288

Article  CAS  PubMed  Google Scholar 

Bossù, P., Ciaramella, A., Salani, F., Bizzoni, F., Varsi, E., Di Iulio, F., et al. (2008). Interleukin-18 produced by peripheral blood cells is increased in alzheimer’s disease and correlates with cognitive impairment. Brain, Behavior, and Immunity, 22(4), 487–492. https://doi.org/10.1016/j.bbi.2007.10.001

Article  CAS  PubMed  Google Scholar 

Caraci, F., Tascedda, F., Merlo, S., Benatti, C., Spampinato, S. F., Munafò, A., et al. (2016). Fluoxetine prevents Aβ(1–42)-induced toxicity via a paracrine signaling mediated by transforming-growth-factor-β1. Frontiers in Pharmacology, 7, Article 389. https://doi.org/10.3389/fphar.2016.00389

Article  CAS  PubMed  PubMed Central  Google Scholar 

Caraci, F., Spampinato, S. F., Morgese, M. G., Tascedda, F., Salluzzo, M. G., Giambirtone, M. C., et al. (2018). Neurobiological links between depression and AD: The role of TGF-β1 signaling as a new pharmacological target. Pharmacological Research, 130, 374–384. https://doi.org/10.1016/j.phrs.2018.02.007

Article  CAS  PubMed  Google Scholar 

Cheishvili, D., Do Carmo, S., Caraci, F., Grasso, M., Cuello, A. C., & Szyf, M. (2025). EpiAge: A next-generation sequencing-based ELOVL2 epigenetic clock for biological age assessment in saliva and blood across health and disease. Aging (Albany NY), 17(1), 131–160. https://doi.org/10.18632/aging.206188

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chung, H., Green, P. H. R., Wang, T. C., & Kong, X. F. (2021). Interferon-driven immune dysregulation in down syndrome: A review of the evidence. Journal of Inflammation Research, 14, 5187–5200. https://doi.org/10.2147/jir.s280953

Article  CAS  PubMed  PubMed Central  Google Scholar 

Díaz-Pino, R., Rice, G. I., San Felipe, D., Pepanashvili, T., Kasher, P. R., Briggs, T. A., et al. (2024). Type I interferon regulates interleukin-1beta and IL-18 production and secretion in human macrophages. Life Science Alliance. https://doi.org/10.26508/lsa.202302399

Article  PubMed  PubMed Central  Google Scholar 

Estrada, L. D., Oliveira-Cruz, L., & Cabrera, D. (2018). Transforming growth factor beta type I role in neurodegeneration: Implications for Alzheimer´s disease. Current Protein and Peptide Science, 19(12), 1180–1188. https://doi.org/10.2174/1389203719666171129094937

Article  CAS  PubMed  Google Scholar 

Felderhoff-Mueser, U., Schmidt, O. I., Oberholzer, A., Bührer, C., & Stahel, P. F. (2005). IL-18: A key player in neuroinflammation and neurodegeneration? Trends in Neurosciences, 28(9), 487–493. https://doi.org/10.1016/j.tins.2005.06.008

Article  CAS  PubMed  Google Scholar 

Flores-Aguilar, L., Iulita, M. F., Kovecses, O., Torres, M. D., Levi, S. M., Zhang, Y., et al. (2020). Evolution of neuroinflammation across the lifespan of individuals with down syndrome. Brain, 143(12), 3653–3671. https://doi.org/10.1093/brain/awaa326

Article  PubMed  PubMed Central  Google Scholar 

Fortea, J., Vilaplana, E., Carmona-Iragui, M., Benejam, B., Videla, L., Barroeta, I., et al. (2020). Clinical and biomarker changes of Alzheimer’s disease in adults with Down syndrome: A cross-sectional study. Lancet, 395(10242), 1988–1997. https://doi.org/10.1016/s0140-6736(20)30689-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Galbraith, M. D., Rachubinski, A. L., Smith, K. P., Araya, P., Waugh, K. A., Enriquez-Estrada, B., et al. (2023). Multidimensional definition of the interferonopathy of down syndrome and its response to JAK inhibition. Science Advances, 9(26), eadg6218. https://doi.org/10.1126/sciadv.adg6218

Article  CAS  PubMed  PubMed Central  Google Scholar 

García, O., & Flores-Aguilar, L. (2022). Astroglial and microglial pathology in Down syndrome: Focus on Alzheimer’s disease. Frontiers in Cellular Neuroscience, 16, Article 987212. https://doi.org/10.3389/fncel.2022.987212

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gensous, N., Franceschi, C., Salvioli, S., Garagnani, P., & Bacalini, M. G. (2019). Down syndrome, ageing and epigenetics. Subcellular Biochemistry, 91, 161–193. https://doi.org/10.1007/978-981-13-3681-2_7

Article  CAS  PubMed  Google Scholar 

Girard, C., Rech, J., Brown, M., Allali, D., Roux-Lombard, P., Spertini, F., et al. (2016). Elevated serum levels of free interleukin-18 in adult-onset Still’s disease. Rheumatology (Oxford, England), 55(12), 2237–2247. https://doi.org/10.1093/rheumatology/kew300

Article  CAS  PubMed  Google Scholar 

Grasso, M., Fidilio, A., L’Episcopo, F., Recupero, M., Barone, C., Bacalini, M. G., et al. (2024). Low TGF-β1 plasma levels are associated with cognitive decline in down syndrome. Frontiers in Pharmacology, 15, 1379965. https://doi.org/10.3389/fphar.2024.1379965

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grotteschi, N., Rochat, M. J., Pollarini, V., Ghezzo, A., Pellegrini, C., Calandra-Buonaura, G., et al. (2025). Neurological findings in a cohort of adults with down syndrome. Neurological Sciences, 46(8), 3639–3649. https://doi.org/10.1007/s10072-025-08195-7

Article  PubMed  PubMed Central  Google Scholar 

Harel, M., Fauteux-Daniel, S., Girard-Guyonvarc’h, C., & Gabay, C. (2022). Balance between Interleukin-18 and Interleukin-18 binding protein in auto-inflammatory diseases. Cytokine, 150, Article 155781. https://doi.org/10.1016/j.cyto.2021.155781

Article  CAS  PubMed  Google Scholar 

Iulita, M. F., Ower, A., Barone, C., Pentz, R., Gubert, P., Romano, C., et al. (2016). An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation. Alzheimer’s & Dementia, 12(11), 1132–1148. https://doi.org/10.1016/j.jalz.2016.05.001

Article  Google Scholar 

Iulita, M. F., Garzón Chavez, D., Klitgaard Christensen, M., Valle Tamayo, N., Plana-Ripoll, O., Rasmussen, S. A., et al. (2022). Association of alzheimer disease with life expectancy in people with down syndrome. JAMA Network Open, 5(5), e2212910. https://doi.org/10.1001/jamanetworkopen.2022.12910

Article  PubMed  PubMed Central  Google Scholar 

Iulita, M. F., Bejanin, A., Vilaplana, E., Carmona-Iragui, M., Benejam, B., Videla, L., et al. (2023). Association of biological sex with clinical outcomes and biomarkers of Alzheimer’s disease in adults with Down syndrome. Brain Communications, 5(2), Article fcad074. https://doi.org/10.1093/braincomms/fcad074

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim, S. H., Eisenstein, M., Reznikov, L., Fantuzzi, G., Novick, D., Rubinstein, M., et al. (2000). Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proceedings of the National Academy of Sciences of the United States of America, 97(3), 1190–1195. https://doi.org/10.1073/pnas.97.3.1190

Article  CAS  PubMed  PubMed Central  Google Scholar 

Larsen, F. K., Baksh, R. A., McGlinchey, E., Langballe, E. M., Benejam, B., Beresford-Webb, J., et al. (2024). Age of Alzheimer’s disease diagnosis in people with Down syndrome and associated factors: Results from the Horizon 21 European Down syndrome consortium. Alzheimer’s & Dementia, 20(5), 3270–3280.